Biotech Values

[DewDiligence]

PFE starts_pivotal_phase-2_trial_of_bispecific-mAb, Elranatamab—(PF-06863135)—in_MM:

https://www.businesswire.com/news/home/20210217005121/en

MagnetisMM-3 is an open-label, multicenter, nonrandomized Phase 2 study of elranatamab monotherapy enrolling approximately 150 people with multiple myeloma who are refractory to at least one proteasome inhibitor, one immunomodulatory drug and one anti-CD38 monoclonal antibody. This study will enroll two cohorts of participants: one with (n=90) and one without (n=60) prior treatment with a BCMA-directed ADC or CAR-T therapy (n=60). Participants will receive a weekly 76 mg subcutaneous injection of elranatamab following a priming dose of 44 mg. The primary endpoint is objective response rate as assessed by blinded independent central review.